An orthopedic surgeon who helped design the all-metal hip implant that Johnson & Johnson (JNJ -0.4%) recalled in 2010 says the device wasn’t defective as he testified in the first of thousands of cases set to go to trial. “I have not used the term ‘defective’” the surgeon testified in a videotaped deposition. JNJ claims the implant was properly designed and the plaintiff's claim of elevated metal levels in his body can be traced to conditions including diabetes, high blood pressure and cholesterol, strokes and kidney cancer. [View news story]
3 Healthcare REITs With Mispriced Risk [View article]
Hot Stocks Of 2004: Where Are They Now? [View article]
An orthopedic surgeon who helped design the all-metal hip implant that Johnson & Johnson (JNJ -0.4%) recalled in 2010 says the device wasn’t defective as he testified in the first of thousands of cases set to go to trial. “I have not used the term ‘defective’” the surgeon testified in a videotaped deposition. JNJ claims the implant was properly designed and the plaintiff's claim of elevated metal levels in his body can be traced to conditions including diabetes, high blood pressure and cholesterol, strokes and kidney cancer. [View news story]
mREITs In 2013 - Friend Or Foe To Dividend Payouts? [View article]